OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL)

Historical Holders from Q3 2014 to Q4 2025

Symbol
OCUL on Nasdaq
Type / Class
Equity / Common stock ("Common Shares")
Shares outstanding
212,883,456
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
188,183,067
Holdings value
$2,200,136,926
% of all portfolios
0.02%
Number of holders
213
Number of buys
119
Number of sells
75
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +22% $371,574,057 +$142,354,542 31,785,634 +62% FMR LLC 30 Sep 2025
Deep Track Capital, LP 6.2% -35% $153,090,545 -$27,615,088 13,095,855 -15% Deep Track Capital, LP 30 Sep 2025
Venrock Healthcare Capital Partners III, L.P. 7.3% $150,957,880 12,913,420 Venrock Healthcare Capital Partners III, L.P. 30 Sep 2025
SUMMER ROAD LLC 5.7% $146,825,720 12,134,357 SUMMER ROAD LLC 04 Dec 2025
BlackRock, Inc. 5.8% $118,890,012 10,170,232 BlackRock, Inc. 30 Sep 2025
Opaleye Management Inc. 2.8% $30,397,500 4,342,500 Opaleye Management Inc. 31 Dec 2024
As of 30 Sep 2025 OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) has 213 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 188,183,067 shares of 212,883,456 outstanding shares and own 88% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) own 74% of the company based on 13F filings as of 30 Sep 2025

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
FMR LLC 15% 31,785,634 +62% 0.02% $371,574,056
VR ADVISER, LLC 6.2% 13,161,462 +3.1% 8.7% $153,857,491
Summer Road LLC 5.9% 12,579,657 -9.4% 99% $147,050,970
Deep Track Capital, LP 5.6% 11,932,137 -17% 3.9% $139,486,682
BlackRock, Inc. 5% 10,556,837 +0.1% 0% $123,409,426
Avoro Capital Advisors LLC 4.8% 10,250,000 +39% 1.6% $119,822,500
VANGUARD GROUP INC 4.3% 9,163,240 +9.2% 0% $107,118,275
TCG Crossover Management, LLC 2.9% 6,117,232 +15% 3.5% $71,510,442
CITADEL ADVISORS LLC 2.7% 5,703,781 +17% 0.05% $66,677,200
Point72 Asset Management, L.P. 2.2% 4,601,321 +142% 0.12% $53,789,442
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.9% 4,004,350 +2.9% 0.07% $46,810,852
MILLENNIUM MANAGEMENT LLC 1.8% 3,855,706 +3136% 0.04% $45,073,203
Paradigm Biocapital Advisors LP 1.6% 3,497,307 +2.3% 1.2% $40,883,519
STATE STREET CORP 1.6% 3,460,012 -1.4% 0% $40,447,540
ALLIANCEBERNSTEIN L.P. 1.6% 3,424,439 +2003% 0.01% $40,031,692
GEODE CAPITAL MANAGEMENT, LLC 1.6% 3,338,453 +1.7% 0% $39,032,331
Logos Global Management LP 1.5% 3,250,000 +48% 3.8% $37,992,500
DELTEC ASSET MANAGEMENT LLC 1.3% 2,762,459 -1.2% 5.3% $32,293,146
Octagon Capital Advisors LP 1.2% 2,624,000 +8.2% 4.8% $30,674,560
MORGAN STANLEY 1.2% 2,465,676 -4.1% 0% $28,823,760
Balyasny Asset Management L.P. 1% 2,189,276 +903% 0.05% $25,592,636
JANUS HENDERSON GROUP PLC 0.96% 2,048,500 +3729% 0.01% $23,957,208
Woodline Partners LP 0.78% 1,666,087 +122% 0.09% $19,476,557
MARSHALL WACE, LLP 0.75% 1,601,449 0.02% $18,720,939
Opaleye Management Inc. 0.75% 1,595,000 0% 2.6% $18,645,550

Institutional Holders of OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 24,159 $238,501 -$26,381 $10.89 2
2025 Q3 188,183,067 $2,200,136,926 +$370,626,573 $11.69 213
2025 Q2 156,434,424 $1,451,692,801 +$187,013,451 $9.28 182
2025 Q1 137,366,906 $1,007,015,553 +$22,122,148 $7.33 195
2024 Q4 133,836,585 $1,142,920,717 -$55,467,873 $8.54 177
2024 Q3 139,959,663 $1,219,694,031 +$26,500,082 $8.70 167
2024 Q2 137,354,354 $939,474,494 +$86,729,069 $6.84 147
2024 Q1 123,356,169 $1,120,774,666 +$444,206,297 $9.10 144
2023 Q4 285,650 $1,288,147 +$426,536 $4.46 3
2023 Q3 40,270,330 $126,445,664 -$13,890,439 $3.14 111
2023 Q2 43,179,624 $222,772,538 +$13,382,124 $5.16 130
2023 Q1 40,134,860 $211,507,415 +$6,216,195 $5.27 123
2022 Q4 39,438,591 $110,821,725 -$11,980,896 $2.81 107
2022 Q3 42,658,981 $177,026,106 -$4,084,786 $4.15 124
2022 Q2 44,187,454 $177,740,871 +$1,507,690 $4.02 118
2022 Q1 43,340,872 $214,625,610 +$8,629,567 $4.95 125
2021 Q4 35,827,526 $249,421,636 -$35,500,739 $6.97 132
2021 Q3 44,352,232 $443,841,670 -$46,156,013 $10.00 136
2021 Q2 48,209,398 $683,549,827 +$13,949,229 $14.18 143
2021 Q1 47,139,902 $773,715,370 -$64,868,300 $16.41 148
2020 Q4 50,237,231 $1,039,869,327 +$212,268,812 $20.70 143
2020 Q3 39,773,072 $302,720,116 +$7,132,421 $7.61 101
2020 Q2 38,676,765 $322,007,676 +$85,253,575 $8.33 103
2020 Q1 28,477,673 $140,961,353 +$17,926,519 $4.95 87
2019 Q4 22,369,194 $88,356,589 +$5,750,969 $3.95 74
2019 Q3 23,087,551 $70,190,921 +$1,029,794 $3.04 70
2019 Q2 19,366,898 $85,218,931 +$2,811,165 $4.40 60
2019 Q1 19,465,269 $77,277,906 +$2,210,655 $3.97 63
2018 Q4 18,664,429 $74,278,322 -$5,799,861 $3.98 63
2018 Q3 21,626,747 $148,790,295 -$1,508,424 $6.88 71
2018 Q2 21,841,690 $147,387,866 +$9,617,897 $6.75 65
2018 Q1 20,397,061 $132,786,813 +$45,673,710 $6.51 62
2017 Q4 12,037,446 $53,583,388 -$12,010,968 $4.45 65
2017 Q3 15,580,222 $96,502,272 -$1,095,075 $6.18 70
2017 Q2 15,253,112 $141,393,882 -$26,304,320 $9.27 70
2017 Q1 18,346,444 $170,228,516 +$20,289,428 $9.28 73
2016 Q4 17,394,280 $145,604,494 -$9,994,743 $8.37 76
2016 Q3 18,785,162 $129,054,713 -$2,940,268 $6.87 70
2016 Q2 19,414,509 $96,096,641 -$30,417,994 $4.95 72
2016 Q1 20,860,674 $201,445,609 -$1,634,265 $9.66 64
2015 Q4 20,957,093 $196,368,107 -$18,083,100 $9.37 70
2015 Q3 20,040,411 $281,763,540 +$49,027,855 $14.06 66
2015 Q2 16,071,389 $337,378,009 +$93,008,051 $21.03 70
2015 Q1 10,685,598 $448,622,275 +$240,819,340 $41.98 55
2014 Q4 5,006,746 $117,752,025 +$9,256,074 $23.52 36
2014 Q3 4,629,882 $69,305,000 +$69,305,017 $14.97 33